Cost-effectiveness study comparing pharmaceutically licensed plasma for transfusion (OctaplasLG®) versus fresh frozen plasma (FFP) in critically Ill patients in the UK

Transfusion and Apheresis Science

Volumn 43, Issue 3, 2010, Pages 251-259

  van Eerd, Margreet C ^a   Mario Ouwens, J N ^a   de Peuter, Maria A ^a  

^a MAPI GROUP   (Netherlands)

Author keywords

Cost effectiveness analysis; Fresh frozen plasma; OctaplasLG ; Transfusion reactions; UK

Indexed keywords

FRESH FROZEN PLASMA; OCTAPLASLG; PLASMA SUBSTITUTE; UNCLASSIFIED DRUG;

ARTICLE; COST EFFECTIVENESS ANALYSIS; CRITICALLY ILL PATIENT; HUMAN; PLASMA TRANSFUSION; QUALITY ADJUSTED LIFE YEAR;

COST-BENEFIT ANALYSIS; CRITICAL ILLNESS; GREAT BRITAIN; HUMANS; PLASMA; PLASMA EXCHANGE; QUALITY-ADJUSTED LIFE YEARS;

EID: 78649482855     PISSN: 14730502     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transci.2010.09.019     Document Type: Article

References (31)

1. Solheim B.G., Seghatchian J. Update on pathogen reduction technology for therapeutic plasma: an overview. Transfus Apher Sci 2006, 35(1):83-90.
2. Riedler G.F., Haycox A.R., Duggan A.K., Dakin H.A. Cost-effectiveness of solvent/detergent-treated fresh-frozen plasma. Vox Sang 2003, 85(2):88-95.
3. Solheim B.G. Pathogen reduction of blood components. Transfus Apher Sci 2008, 39:75-82.
4. Krusius T., Auvinen M.K., Nikkinen L. Introduction of OctaplasLG® in clinical use decreased the rate of severe adverse reactions. Vox Sang 2009, 96:33.
5. Neisser-Svae A., Bailey A., Gregori L., Heger A., Jordan S., Behizad M., et al. Prion removal effect of a specific affinity ligand introduced into the manufacturing process of the pharmaceutical quality solvent/detergent (S/D)-treated plasma octaplasLG®. Vox Sang 2009, 1-9.
6. Vaara I, Backlund B, Bratt M, Nilsson C, Gustavsson K. Documentation of adverse events after use of FFP and octaplasLG®. XXXth international congress: international society of blood transfusion; 2008.
7. Membe SK, Coyle D, Husereau D, Cimon K, Tinmouth A, Normandin S. OctaplasLG® compared with fresh frozen plasma to reduce the risk of transmitting lipid-enveloped viruses: an economic analysis and budget impact analysis; 2009. Available from: http://www.cadth.ca/media/pdf/I4002_Octaplas%20versus%20FFP_L4_e_April%202009.pdf.
8. National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal; 2008.
9. Taylor C, Cohen H, Mold D, Jones H, editors, on behalf of the Serious Hazards of Transfusion (SHOT) steering group. The 2008 Annual SHOT Report; 2009.
10. Gajic O., Rana R., Winters J.L., Yilmaz M., Mendez J.L., Rickman O.B., et al. Transfusion-related acute lung injury in the critically ill: prospective nested case-control study. Am J Respir Crit Care Med 2007, 176(9):886-891.
11. Wright S.E., Snowden C.P., Athey S.C., Leaver A.A., Clarkson J.M., Chapman C.E., et al. Acute lung injury after ruptured abdominal aortic aneurysm repair: the effect of excluding donations from females from the production of fresh frozen plasma. Crit Care Med 2008, 36(6):1796-1802.
12. AuBuchon J.P., Birkmeyer J.D. Safety and cost-effectiveness of solvent-detergent-treated plasma. In search of a zero-risk blood supply. JAMA 1994, 272(15):1210-1214.
13. Pereira A. Cost-effectiveness of transfusing virus-inactivated plasma instead of standard plasma. Transfusion 1999, 39(5):479-487.
14. Marshall D.A., Kleinman S.H., Wong J.B., AuBuchon J.P., Grima D.T., Kulin N.A., et al. Cost-effectiveness of nucleic acid test screening of volunteer blood donations for hepatitis B, hepatitis C and human immunodeficiency virus in the United States. Vox Sang 2004, 86(1):28-40.
15. Davies L, Brown TJ, Haynes S, Payne K, Elliott RA, McCollum C. Cost-effectiveness of cell salvage and alternative methods of minimising perioperative allogeneic blood transfusion: a systematic review and economic model. Health Technol Assess 2006;10(44):iii-x.
16. Jones C. Focus on consumer price indices. Available from: 2009 Oct. http://www.statistics.gov.uk/downloads/theme_economy/Focus_on_CPI_Oct_09.pdf.
17. Phillips of Worth Matravers L, Bridgeman J, Ferguson-Smith M. The inquiry into BSE variant CJD in the United Kingdom. Available from: 2000. http://web.archive.org/web/20010306231441/www.bseinquiry.gov.uk/report/volume8/chapter6.htm.
18. Custer B., Hoch J.S. Cost-effectiveness analysis: what it really means for transfusion medicine decision making. Transfus Med Rev 2009, 23(1):1-12.
19. Wallis J.P., Wells A.W., Matthews J.N., Chapman C.E. Long-term survival after blood transfusion: a population based study in the North of England. Transfusion 2004, 44(7):1025-1032.
20. Bauch C.T., Anonychuk A.M., Pham B.Z., Gilca V., Duval B., Krahn M.D. Cost-utility of universal hepatitis A vaccination in Canada. Vaccine 2007, 25(51):8536-8548.
21. Kleinman S., Chan P., Robillard P. Risks associated with transfusion of cellular blood components in Canada. Transfus Med Rev 2003, 17(2):120-162.
22. Kanwal F., Gralnek I.M., Martin P., Dulai G.S., Farid M., Spiegel B.M. Treatment alternatives for chronic hepatitis B virus infection: a cost-effectiveness analysis. Ann Intern Med 2005, 142(10):821-831.
23. El Saadany S., Coyle D., Giulivi A., Afzal M. Economic burden of hepatitis C in Canada and the potential impact of prevention. Results from a disease model. Eur J Health Econ 2005, 6(2):159-165.
24. Chancellor J.V., Hill A.M., Sabin C.A., Simpson K.N., Youle M. Modelling the cost effectiveness of lamivudine/zidovudine combination therapy in HIV infection. Pharmacoeconomics 1997, 12(1):54-66.
25. Angus D.C., Musthafa A.A., Clermont G., Griffin M.F., Linde-Zwirble W.T., Dremsizov T.T., et al. Quality-adjusted survival in the first year after the acute respiratory distress syndrome. Am J Respir Crit Care Med 2001, 163(6):1389-1394.
26. National Blood Service. Available from: 2009. http://hospital.blood.co.uk/library/pdf/Price_List_B_BC_2009_10.pdf.
27. Thompson C.J., Rogers G., Hewson P., Wright D., Anderson R., Cramp M., et al. Surveillance of cirrhosis for hepatocellular carcinoma: systematic review and economic analysis. Health Technol Assess 2007, 11(34):1-206.
28. UK Department of Health. Available from: 2009. http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/documents/digitalasset/dh_4140185.xls.
29. UK Department of Health. Available from: 2009. http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/documents/digitalasset/dh_081247.xls.
30. Aids Treatment Update. Available from: 2009. http://www.aidsmap.com/files/file1000632.pdf.
31. Beck E.J., Tolley K., Power A., Mandalia S., Rutter P., Izumi J., et al. The use and cost of HIV service provision in England in 1996. National prospective monitoring system (NPMS) steering group and NPMS working party on costs. Pharmacoeconomics 1998, 14(6):639-652.